In recent years, there has been great interest in the concept of a clustering of risk factors for cardiovascular disease (CVD) occurring in a given individual to a greater degree than expected by chance. This clustering, commonly referred to as the “metabolic syndrome,” has clinical manifestations frequently observed in obesity and is believed to be associated with underlying insulin resistance (IR) in the majority, of individuals. In its original conception, “syndrome X” [1] or the “insulin resistance syndrome” [2] provided a framework to understand the relationship or association between IR, multiple metabolic abnormalities, and the development of type 2 diabetes mellitus (T2DM). This “metabolic” clustering of risk factors (obesity, elevated triglycerides [TG] and low high-density lipoprotein [HDL] cholesterol, hypertension, IR, abnormal fasting or 2-h plasma glucose levels, and others) is used primarily to CVD risk profiling in an individual subject.

Risk relationship between insulin resistance, diabetes, and atherosclerotic cardiovascular disease

Del Turco S.;Sicari R.;Gastaldelli A.
2014

Abstract

In recent years, there has been great interest in the concept of a clustering of risk factors for cardiovascular disease (CVD) occurring in a given individual to a greater degree than expected by chance. This clustering, commonly referred to as the “metabolic syndrome,” has clinical manifestations frequently observed in obesity and is believed to be associated with underlying insulin resistance (IR) in the majority, of individuals. In its original conception, “syndrome X” [1] or the “insulin resistance syndrome” [2] provided a framework to understand the relationship or association between IR, multiple metabolic abnormalities, and the development of type 2 diabetes mellitus (T2DM). This “metabolic” clustering of risk factors (obesity, elevated triglycerides [TG] and low high-density lipoprotein [HDL] cholesterol, hypertension, IR, abnormal fasting or 2-h plasma glucose levels, and others) is used primarily to CVD risk profiling in an individual subject.
2014
Istituto di Fisiologia Clinica - IFC
Cardiometabolic risk; Endothelial dysfunction; Insulin resistance; Insulin signaling pathways; Drug Discover; Pharmaceutical Science; Pharmacology
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/564383
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ente

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact